John Divine

InvestorPlace Assistant Editor

John Divine is currently an investing reporter at U.S. News & World Report, and was previously an assistant editor at InvestorPlace.com. He has worked variously in the fields of commercial real estate, money management and digital media, working as a financial journalist for most of his professional career.

John has also been a regular contributor to The Motley Fool, and his work also has appeared on AOL DailyFinance.

In 2013, he shortened his bucket list when he saw Warren Buffett live and in the flesh while covering the Berkshire Hathaway Annual Shareholders’ Meeting.

A proud North Carolinian and graduate of Appalachian State University, John majored in Finance & Banking. He enjoys basketball, reading, writing and food. He does not care for the Oxford comma, and he does not require the food he enjoys to be nutritious.

Recent Articles

5 Blue-Chip Stocks of Tomorrow to Buy Today

By John Divine, InvestorPlace Assistant Editor Mar 24, 2015

While the hunt is always on for the best blue-chip stocks to buy now, the search gets a little more difficult when you try to predict the companies that will be blue-chip stocks tomorrow.

This Laser-Like Focus Makes Facebook (FB) Stock A Screaming Buy

By John Divine, InvestorPlace Assistant Editor Mar 24, 2015

Facebook (FB) is laser-focused on luring Silicon Valley's brightest to partner with and improve its emerging services like messaging and virtual reality.

The 10 Best States to Retire In 2015: Where Does Your State Rank?

By John Divine, InvestorPlace Assistant Editor Mar 23, 2015

The 10 best states to retire in 2015 might surprise you. The 10 worst might come as a shock, too. Where does your state rank?

GrubHub (GRUB) Stock WILL Be Acquired — But Is It a Buy Right Now?

By John Divine, InvestorPlace Assistant Editor Mar 23, 2015

GrubHub (GRUB) stock looks like an imminent buyout candidate, especially after two competitors were snapped up in the last year. But is it a buy?

Biogen (BIIB) Stock: Promising Alzheimer’s Drug Could Reap Billions

By John Divine, InvestorPlace Assistant Editor Mar 20, 2015

Biogen Idec (BIIB) stock rallied today after an early-stage Alzheimer's drug slowed mental declines rapidly. The potential market is too large to ignore.